The type 1 insulin-like growth factor receptor (IGF-1R) and its downstream 
signaling components have become increasingly recognized as having a driving 
role in the development of malignancy, and consequently IGF-1R has become a 
potential target for cancer therapy. Several inhibitors of IGF-1R are in 
clinical development for the treatment of solid tumors, including non-small cell 
lung cancer (NSCLC). These IGF-1R-targeted agents include monoclonal antibodies 
such as cixutumumab (IMC-A12), AMG-479, AVE1642, BIIB022, dalotuzumab (MK-0646), 
and robatumumab (Sch717454), the ligand neutralizing antibody Medi-573, and the 
small molecule inhibitors BMS-754807, linsitinib (OSI-906), XL228, and AXL1717. 
Two phase III trials of the anti-IGF-1R monoclonal antibody, figitumumab 
(CP-751,871), were discontinued in 2010 as it was considered unlikely either 
trial would meet their primary endpoints. In light of disappointing clinical 
data with figitumumab and other targeted agents, it is likely that the use of 
molecular markers will become important in predicting response to treatment. 
This review outlines the role of IGF-1R signaling in solid tumors with a 
particular focus on NSCLC, and provides an overview of clinical data.